Cumberland Pharms Company Profile

What is the competitive landscape for CUMBERLAND PHARMS, and what generic alternatives to CUMBERLAND PHARMS drugs are available?

CUMBERLAND PHARMS has six approved drugs.

There are seventeen US patents protecting CUMBERLAND PHARMS drugs.

There are one hundred and eighty-four patent family members on CUMBERLAND PHARMS drugs in thirty-nine countries and fifteen supplementary protection certificates in fourteen countries.

Summary for Cumberland Pharms

International Patents:	184
US Patents:	17
Tradenames:	7
Ingredients:	6
NDAs:	6

Drugs and US Patents for Cumberland Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cumberland Pharms	ACETADOTE	acetylcysteine	INJECTABLE;INTRAVENOUS	021539-001	Jan 23, 2004	AP	RX	Yes	Yes	8,722,738
Cumberland Pharms	CALDOLOR	ibuprofen	SOLUTION;INTRAVENOUS	022348-002	Jun 11, 2009		RX	Yes	Yes	9,114,068
Cumberland Pharms	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-002	Sep 11, 2009		RX	Yes	Yes	7,531,623			Y
Cumberland Pharms	CALDOLOR	ibuprofen	SOLUTION;INTRAVENOUS	022348-003	Jan 25, 2019		RX	Yes	Yes	8,735,452
Cumberland Pharms	CALDOLOR	ibuprofen	SOLUTION;INTRAVENOUS	022348-002	Jun 11, 2009		RX	Yes	Yes	8,735,452
Cumberland Pharms	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-001	Sep 11, 2009		DISCN	Yes	No	7,531,623			Y
Cumberland Pharms	ACETADOTE	acetylcysteine	INJECTABLE;INTRAVENOUS	021539-001	Jan 23, 2004	AP	RX	Yes	Yes	8,399,445

Expired US Patents for Cumberland Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cumberland Pharms	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-002	Sep 11, 2009	7,351,691
Cumberland Pharms	VAPRISOL	conivaptan hydrochloride	INJECTABLE;INTRAVENOUS	021697-001	Dec 29, 2005	5,723,606
Cumberland Pharms	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-001	Sep 11, 2009	8,101,575
Cumberland Pharms	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-002	Sep 11, 2009	6,858,584
Cumberland Pharms	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-001	Sep 11, 2009	7,208,471
Cumberland Pharms	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-001	Sep 11, 2009	7,700,550
Cumberland Pharms	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-001	Sep 11, 2009	8,158,580

Paragraph IV (Patent) Challenges for CUMBERLAND PHARMS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Injection	200 mg/mL, 30 mL vials		2012-04-04

International Patents for Cumberland Pharms Drugs

Country	Patent Number	Estimated Expiration
South Korea	20120138229
Slovenia	1276759
Canada	2766367
Malaysia	173215
Australia	5746401
Japan	2004501161
Norway	2011025

Supplementary Protection Certificates for Cumberland Pharms Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1292612	PA2012002,C1292612	Lithuania		PRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902
1292612	132012902025885	Italy		PRODUCT NAME: TELAVANCINA(VIBATIV); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/705/001-002, 20110902
1292612	2011C/045	Belgium		PRODUCT NAME: VIBATIV - TELAVANCINE; AUTHORISATION NUMBER AND DATE: EU/1/11/705-001 20110902
1292612	PA2012002	Lithuania		PRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902
1292612	122011100062	Germany		PRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
1292612	91908	Luxembourg		91908, EXPIRES: 20260501
1292612	C300507	Netherlands		PRODUCT NAME: TELAVANCINE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, INCLUSIEF TELAVANCINE HYDROCLORIDE; REGISTRATION NO/DATE: EU/1/11/705/001 - 002 20110902

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Cumberland Pharms
• Cumberland Swan